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10.1016/j.ejps.2013.02.011In recent years the use of solid lipid nanoparticles (SLNs) as transport systems for the delivery of drugs
and biomolecules has become particularly important. The use of cationic SLNs developed by the tech-
nique of microemulsion, which are complexed with DNA in order to study their application as non-viral
vectors in gene therapy, is reported. The nanoparticles are characterized by scanning electron microscopy
and transmission electron microscopy (SEM and TEM), atomic force microscopy (AFM) and differential
scanning calorimetry (DSC). Furthermore, the process of lyophilization of the samples and their stability
was studied. The nanoparticles obtained presented a particle size of 340 nm with a positive surface
charge of 44 mV and the capability of forming lipoplexes with DNA plasmids was stated.
 2013 Published by Elsevier B.V.3557
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771. Introduction
Nanoscience and nanotechnology have received much attention
in the last decade and they now form one of the most important
fields of technology and innovation. It is a field that has attracted
the attention of both industry and governments around the
world (Dowling, 2004; Zweck et al., 2008; Aguar Fernandez and
Hullmann, 2007).
Due to rapid progresses in nanotechnology and biotechnology,
nanoparticles have come to be seen as a viable vehicle for the
delivery and release of drugs. Nanoparticles have thus advanced
rapidly in the pharmaceutical world and their production and
application in biomedicine has become one of the most important
developments in nanotechnology and nanoscience (Nowack and
Bucheli, 2007; Medina et al., 2007; Wong et al., 2012).
Within this field, the use of solid lipid nanoparticles (SLNs) is of
particular importance. SLNs comprise a variety of systems with a
particle diameter of between 50 and 1000 nm, and their proprieties
make them a viable alternative to polymeric systems (Battaglia
et al., 2010; Mehnert and Mäder, 2012). They are colloidal particles
made up of a relatively rigid biocompatible and biodegradable ma-78
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al. DNA delivery via cationic strix of hydrophobic lipids that are solid at room and body
temperatures.
SLNs have experienced constant development over recent years
as drug delivery systems, although there is not much literature
concerning their application in gene therapy. Their capacity to
transfect cells in vitro has been demonstrated (Olbrich et al.,
2001; Tabatt et al., 2004; del Pozo-Rodríguez et al., 2008, 2010;
Martins et al., 2012) since the 1990s when Müller (1991) and
Gasco (1993) first studied the proprieties of SLNs in drug delivery.
SLNs were originally designed as an alternative to liposomes
and emulsions. Although liposomes present a series of advantages
(encapsulation of both hydrophilic and hydrophobic active ingredi-
ents, reduced toxicity and increased therapeutic efficiency of active
ingredients that is not achieved with other systems), their applica-
tion has seen only limited success (Borchard, 2001). Such limita-
tions are due to the complexity associated with the process of
obtaining liposomes, scaling difficulties, their limited stability
and the high cost of their formulation (Joshi and Müller, 2009).
SLNs have the advantages of colloidal systems of drug delivery,
such as liposomes, polymeric nanoparticles and emulsions, while
at the same time they considerably minimize or reduce the incon-
veniences associated with these systems. Some of their advantages
include the ability to integrate both hydrophilic and hydrophobic
drugs as well as the ability to prolong active ingredient release
or to immobilize it in the solid matrix. These SLNs properties com-
pared to polymeric nanoparticles are based on their low cytotoxic-
ity, high capacity for transfection, better stability in biologicalolid lipid nanoparticles (SLNs). Eur. J. Pharm. Sci. (2013), http://dx.doi.org/
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2 March 2013systems and improved scalability (Blasi et al., 2007; Wissing et al.,
2004; Marengo et al., 2000; Müller et al., 2000; Wang et al., 2012).
Gene therapy is the set of techniques by means of which frag-
ments of DNA or RNA can be delivered to the inside of specific cells
in order to modulate the expression or suppression of the biosyn-
thesis of specific altered proteins so as to reverse a biological dis-
order and treat disease (Ledley, 1996; Corsi et al., 2003).
Gene delivery systems include both viral and non-viral vectors.
A wide variety of vectors for the delivery of genetic material have
been studied (Nishikawa and Hashida, 2002). Viral vectors are one
of the strategies more generally used and are the dominant sys-
tems for gene delivery with high transfection efficiency. However,
viral vector applications are limited due to the adverse effects asso-
ciated with them such as their immunogenicity and oncogenicity
(Wu and Ataai, 2000; Richardson et al., 1999; De Laporte et al.,
2006). These limitations have led to the development of effective
synthetic systems for delivering DNA incorporating the DNA in
nanoparticles while aiming to maintain the advantages of viral
vectors.
A large number of non-viral vectors have been studied and ap-
plied as non-natural systems of stable transfection that contain
low toxicity and are non-immunogenic since they can auto-assem-
ble with the DNA and form nanoparticles capable of being trans-
ported to the cells (Davis, 2002; He et al., 2010; Ewert et al.,
2005; Li and Huang, 2007; Ferrer-Miralles et al., 2008; Rogers
and Rush, 2012; Liang et al., 2012).
Non-viral vectors include cationic lipids. The electrostatic inter-
action between the negative charges of the DNA and the positive
charges of the lipid allow the formation of a complex called lipo-
plex. These lipoplexes can form a structure that protects the DNA
and which is able to direct it towards the target cells (Pedersen
et al., 2006; Faneca et al., 2002; del Pozo-Rodríguez et al., 2007;
Duarte et al., 2012).
Our purpose is to develop a method for obtaining cationic SLNs
capable of forming a complex with DNA plasmids. A series of char-
acteristics for the particles to be considered good non-viral vector
are required. On the one hand, they must be nanometric in size
with a suitable surface charge to form complexes with DNA plas-
mids, and on the other hand they must be stable.179
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1952. Materials and methods
2.1. Materials
Stearylamine (Sigma–Aldrich, Barcelona, Spain), 2-methyloxi-
rane as a hydrophilic non-ionic surfactant (Poloxamer 188-BASF,
Germany), glycerol distearate (Precirol ATO-5-Gattefosé,
France), trehalose (Cerestar, Barcelona, Spain), mannitol (Fagron,
Barcelona, Spain). The media used are DMEM (Dulbeco’s Modified
Eagle’s Medium, PAA Laboratories, Austria), DMEM supplemented
with penicillin (100 U/ml) and streptomycin (100 lg/ml) (Invitro-
gen) and HBS (Hepes buffered saline, Sigma–Aldrich, Barcelona,
Spain). The plasmid DNA used is pMS2-TCERG1 plasmid of approx-
imately seven kilobases that contains the cDNA encoding the car-
boxyl region of the human transcription factor TCERG1 (Suñé
et al., 1997), purified with Qiagen kits (Hilden, Germany).196
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2032.2. Methods
2.2.1. Obtaining the SLNs
To obtain cationic SLNs, a modification of the method described
has been used (Vighi et al., 2007; Bondi’ et al., 2007). The SLNs are
obtained from a microemulsion (O/W) using Precirol ATO-5 and
stearylamine as the cationic lipid. 500 mg of Precirol ATO-5 is
heated to 10 C above its melting point, and 10 ml of a hot aqueousPlease cite this article in press as: Carrillo, C., et al. DNA delivery via cationic s
10.1016/j.ejps.2013.02.011solution of poloxamer and stearylamine in different proportions
(1/1.25; 1/1.87; 1/3.12; 1/4.37 and 1/5 respectively) is added. The
sample is stirred for 30 min at 14,000 rpm (IKA T25 digital Ultra-
Turrax, Staufen, Germany). The nanoparticles are obtained by dis-
persing the hot microemulsion in cold water (between 2 C and
5 C) in an emulsion:water ratio of 1:5. To recover nanoparticles,
the resultant suspension is centrifuged for three times at
3000 rpm for 20 min at a temperature of 20 C, reconstituting the
precipitate after centrifugation. Part of the fresh sample is then
stored at 4 C, while the other part of the sample is lyophilized.
2.2.2. Lyophilization of samples
Cationic SLNs are lyophilized by being added an aqueous solu-
tion of cryoprotectant in the proportion 1:2 (SLN:cryoprotectant).
Mannitol and trehalose are the cryoprotectants used in the study
(of 5% and 10% in both cases). The freezing temperature is set at
40 C in the lyophilizer Telstar L-3 (Telstar, Terrassa, Spain),
and samples are kept at this temperature for 2 h. Lyophilization
temperature is then set to 25 C at a pressure of 0.2–0.4 mBa for
48 h.
2.2.3. Determination of particle size
The distribution of the particle size of the cationic SLNs is deter-
mined by laser diffraction technique (Mastersizer 2000, Malvern
Instruments, UK), by dispersing the sample with bidistilled water
in the Hydro dispersion module (Malvern Instruments, UK). Parti-
cle size is determined in triplicate, and the mean value is calcu-
lated. The size data are evaluated using the following distribution
volumes: d10%, d50% and d90% (European Pharmacopoeia, 2012).
2.2.4. Determination of surface charge
Particles zeta-potential values are determined by using the light
dispersion technique with Zetasizer Nano Z equipment (Malvern
Instruments, UK). An amount of sample is placed in the capillary
cell for samples in aqueous media at a predetermined temperature
of 25 C. Surface charge is measured three times and the mean va-
lue taken.
2.2.5. Electron microscopy and atomic force microscopy (AFM)
The morphology of the cationic SLNs is studied by electron
microscopy both scanning electron microscopy (Hitachi S-2300,
Japan) and transmission electron microscopy (Hitachi 800MT, Ja-
pan), and in this way their shape and size are characterized.
Atomic force microscopy (AFM) is used to study the topography
of the samples: their morphology and their particle size. Extended
Multimode equipment is used for the AFM with Nanoscope IV
(Veeco, Mannheim, Germany) and images are captured in Peak
Force mode. A silicon nitride cantilever probe with silicon oxide
tips of 0.35 nN/nm (SNL-10, Bruker, USA) is used.
2.2.6. Differential scanning calorimetry (DSC)
The thermal stability of the compounds is studied using the dif-
ferential scanning calorimetry (DSC) equipment DSC-822e/700
(Mettler Toledo, Spain) at temperatures of between 30 C and
300 C for 30 min (10 C/min). Between 2 and 5 mg of each of the
components of the formulation is individually subjected to DSC, to-
gether with binary and tertiary mixtures of them, and also both
lyophilized and fresh (non-lyophilized) SLNs.
2.2.7. Stability
The study of stability is carried out by preparing the samples in
hermetically sealed glass vials at a temperature of 30 C ± 2 C.
Samples’ morphology and appearance are then analyzed together
with the pH and the superficial charge of the nanoparticles at dif-
ferent times: t = 0; 24 h; 10 days and 30 days in order to detect
physical or chemical changes (Mora-Huertas et al., 2010). Theolid lipid nanoparticles (SLNs). Eur. J. Pharm. Sci. (2013), http://dx.doi.org/
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Table 1
Average results (±SD; n = 3) of the size and zeta-potential of the SLNs (stearyl-
amine:poloxamer proportions 1:1.25).
Particle size (nm) Zeta-potential (mV)
342.3 ± 0.076 43.98 ± 1.58
Table 2
Particle size for SNL samples with cryoprotectant before lyophilization, lyophilizated
samples with different cryoprotectant reconstituted with water but no sonication and
lyophilizated samples with cryoprotectant reconstituted with both water and
sonication.
Cryoprotectant Particle size
before
lyophilization
(nm)
Water + stirring
(lm)
Water + sonication
(lm)
Trehalose 10% 325 ± 0.04 0.338 ± 0.06 0.309 ± 0.005
Mannitol 10% 269 ± 6.65 58.69 ± 4.91 30.446 ± 3.33
Trehalose 5% 252 ± 6.43 12.64 ± 1.19 0.264 ± 0.007
Mannitol 5% 296 ± 10.21 43.13 ± 2.79 22.41 ± 0.44
SLN 252 ± 1.15 –a –a
a In the SLN samples without a cryoprotectant, particle size values could not be
stated due to the formation of agglomerations.
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otics (DMEM-Ab) and HBS.
2.2.8. Formation of the SLN-plasmid DNA complex
A solution of plasmid DNA is prepared to a concentration of
2 lg/ll. Then 25-ll aliquot of the plasmid DNA solution is added
to different volumes of a suspension of the cationic SLNs to obtain
ratios of between 15:1 and 1:1 (SLN:DNA) by stirring (del Pozo-
Rodríguez et al., 2008). SLN-plasmid DNA complex is formed as
shown in Fig. 1.
2.2.9. Agarose gel electrophoresis
The interaction of nanoparticles with the plasmid DNA is stud-
ied via the electrophoretic mobility of the samples in agarose gel.
After a 30 min period of incubation, the loading efficiency of the
nanoparticles to encapsulate the DNA is evaluated by using the
DNA pattern that depends on the quantity of plasmids that remain
free in the agarose gel.
For the DNA electrophoretic gel separations, agarose D-1 Media
EEO (Pronadisa) 0.8% in Tris-acetate-EDTA (TAE) 1X (Tris acetate
40 mM, EDTA 1 mM) with 0.5 lg/ml of ethidium bromide is used.
Power sources, cuvettes and accessories are all from BioRad.
The 6X loading buffer used consists of 0.25% (p/v) bromophenol
blue, 0.25% xylene cyanol FF and 30% (v/v) glycerol. The molecular
weight marker used is a 1 kb DNA ladder from New England Bio-
Labs. Once resolved in the agarose gels, samples are visualized
in a Gel Doc (BioRad) station using the QuantityOne program
for gels stained with ethidium bromide.
3. Results and discussion
After the cationic SLNs was obtained using the microemulsion
method described above, the nanoparticles were characterized,
the lyophilized samples studied and the stability was assessed
with the below detailed results.
3.1. Size and zeta-potential of the nanoparticles
For the characterization of the SLN formulations, an initial study
was performed by varying the quantity of stearylamine. Once sev-
eral particle size and zeta-potential results were obtained (be-
tween 342–442 nm and 43–59 mV), it was observed that
nanoparticles obtained with stearylamine:poloxamer proportions
1:1.25, had a better size–charge relationship; smaller cationic SLNs
with a higher zeta-potential were obtained (Table 1). Therefore,
this proportion was chosen as the working formulation.
3.2. Lyophilization process
Part of the fresh cationic SLNs obtained by microemulsion was
diluted with the different cryoprotectants prior to being lyophi-
lized. Before lyophilization, the particle size of the different sus-
pensions was determined with the results shown in Table 2. The
particle sizes were between 250 and 330 nm, approximately.
Once the process of lyophilization was complete, the visual
appearance of the vials was analyzed. In all the samples containingFig. 1. Representative structure for condensed plasmid DNA on the outside o
Please cite this article in press as: Carrillo, C., et al. DNA delivery via cationic s
10.1016/j.ejps.2013.02.011cryoprotectant, the lyophilized tablet was observed to be in perfect
condition while for the vials that contained the cationic SLNs sam-
ple without any cryoprotectant, the tablet was broken and/or
moved due to possible microboiling.
Particle sizes were determined by resuspending the lyophilized
samples in bidistilled water followed by stirring for a few seconds
(Table 2). The best results were observed for the samples that con-
tained the trehalose as a cryoprotectant, specifically at a concen-
tration of 10%, with a particle size that was practically the same
as that of the initial sample. After 2 min of sonication, the same
sample yielded a slightly smaller particle size: approximately
310 nm.
For the samples containing trehalose at 5%, and after sonication,
a nanometric particle size was also observed, while for the samples
containing the mannitol cryoprotectant, the resultant particle size
was never below 20 lm, irrespective of the concentration.
Resuspension of the cationic SLNs with no cryoprotectant
proved to be quite difficult, even after more than 20 min of sonica-
tion; agglomerates of several micrometres (30–40 lm) were
formed. This behavior indicated that the sample had become de-
graded due to possible microboiling during the lyophilization
process.3.3. Electron microscopy and AFM
Electron microscope images are shown in Fig. 2a–d. The cationic
SLNs appear as smooth spheres with a size similar to that obtained
by laser diffraction.
Morphology and particle size were analyzed by topography
through the AFM images of the cationic SLNs as shown in Fig. 3.
Particles seemed to be polydisperse and in order to determine
the particles size, a number of independent particles were chosenf the cationic SLNs (lipoplex) formed through electrostatic interactions.
olid lipid nanoparticles (SLNs). Eur. J. Pharm. Sci. (2013), http://dx.doi.org/
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Fig. 2. Electron microscope photographs of SLNs (before lyophilization): by transmission electron microscopy (2a) and by scanning electron microscopy (2b–2d).
Fig. 3. Atomic force microscopy image of the SLN samples. White arrows are
pointing out some cationic SLNs.
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2 March 2013at random (n = 20) so that their average diameter could be calcu-
lated. The result was 230 nm (±95 nm). Comparing this with the
value given in Section 3.2, this particle size agrees with that found
when using the laser diffraction technique. On the one hand, the
margin of error was greater for AFM due to the subjectivity in-
volved and the manual calculation of the diameters, while on thePlease cite this article in press as: Carrillo, C., et al. DNA delivery via cationic s
10.1016/j.ejps.2013.02.011other hand the size of the smallest particles was better determined
by AFM.
The topographic study revealed that smooth spherical nano-
metric particles had been obtained.
3.4. DSC
The DSC diagrams for all the components in the formulation and
their combinations, together with those of the non-lyophilized cat-
ionic SLN samples and the different lyophilized samples shaped the
results shown in Figs. 4–7.
The DSC curves of all the excipients used in the formulation of
the cationic SLNs (Fig. 4) showed that there were no interactions
between the products, since the only melting points to be observed
were the normal ones. This fact ruled out the possibility that the
lyophilization process caused any type of polymorph to form.
A comparison of the DSC diagrams for the two samples shown
in Fig. 5 (non-lyophilized and lyophilized without a cryoprotec-
tant) shows differences that indicate an alteration in the character-
istics of the sample. There is an exothermic peak in the absence of
the cryoprotectant, which demonstrates the degradation of the
product. This corresponds with the observation of the broken
and/or moved tablet, as well as with the increased difficulty in
reconstituting it.
For the cationic SLNs lyophilized with the trehalose cryoprotec-
tant (Fig. 6), the glass transition temperature of the sugar can be
seen at approximately 123 C, while the signal from the SLNs re-
mains at 65–68 C. This leads us to consider that the process of
lyophilization does not alter the quality of the product.
Results obtained from the lyophilized samples with 5% and 10%
concentrations (Fig. 7) of the mannitol cryoprotectant, some small
melting signals could be observed at a temperature close to that of
the SLNs. In both cases, interactions or degradation products ap-
peared at approximately 155 C, which indicated that the use of
mannitol did not sufficiently stabilize the cationic SLNs in the
lyophilization process.olid lipid nanoparticles (SLNs). Eur. J. Pharm. Sci. (2013), http://dx.doi.org/
Fig. 4. DSC results for all the components of the formulation of the cationic SLN and their combinations.
Fig. 5. DSC of cationic SLN samples in the solid state without lyophilization and lyophilized SLNs with no cryoprotectant.
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Fig. 6. (a) DSC of lyophilized cationic SLN samples with the cryoprotectant trehalose at a concentration of 5% and 10%; (b) DSC of trehalose.
Fig. 7. (a) DSC of lyophilized cationic SLN samples with the cryoprotectant mannitol at a concentration of 5% and 10%; (b) DSC of mannitol.
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Fig. 8. pH of the samples as a function of time for the different media.
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Fig. 9. Zeta-potential values of the samples as a function of time (t = 0, 24 h, 10 days
and 30 days) for the different media.
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Results of the analysis of the samples after different times (t = 0,
24 h, 10 days and 30 days) at 30 C in the determinations of the pH
and surface charge of the medium are shown (Figs. 8 and 9). In or-
der to establish which values are due to the characteristics of the
medium itself rather than due to the actual sample, pH and zeta-
potential values of the media without the cationic SLNs were taken
as a baseline reference (Table 3).Please cite this article in press as: Carrillo, C., et al. DNA delivery via cationic s
10.1016/j.ejps.2013.02.011Fig. 8 represents pH results. DMEM’s pH range is known (6.8–
8.2) and pH changes indicate medium degradation. In general, a
progressive decrease in the value of pH of the cationic SLNs in all
the media can be seen as time increase. This decrease in pH is more
marked for the cationic SLNs without a medium. This trend is also
seen for the value of the surface charge (Fig. 9), since a decrease in
the zeta-potential value is observed, although it becomes more
pronounced after 10 days.olid lipid nanoparticles (SLNs). Eur. J. Pharm. Sci. (2013), http://dx.doi.org/
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Table 3
Medium pH and zeta-potential values with no SLNs addition.
Medium pH Z-potential (mV)
DMEM 8.34 7
DMEM-Ab 8.03 12
HBS 6.87 30
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charge of the particles depended on several factors, such as the
chemical composition of the surface, the type of solvent, the pH
of the medium and the concentration of the sample (Carneiro-
da-Cunha et al., 2011; Liao et al., 2009), the zeta-potential indi-
cated the stability of the colloidal system. The values to consider
the stability of a particle must be above +30 mV and belowFig. 10. SEM images for the SLN samples stored at 30 ± 2 C in DMEM mediu
Fig. 11. SEM images for the SLN samples stored at 30 ± 2 C in DMEM medium
Fig. 12. SEM images for the SLN samples stored at 30 ± 2 C in DMEM medium
Please cite this article in press as: Carrillo, C., et al. DNA delivery via cationic s
10.1016/j.ejps.2013.02.01130 mV, since large zeta-potentials facilitate repulsive forces indi-
cating stability, while values in the range between +30 and
30 mV facilitate the attraction of the particles indicating instabil-
ity and flocculation.
For all the above mentioned, the cationic SLNs without the addi-
tion of a medium can be considered stable up to approximately
10 days. Nevertheless, and bearing in mind that the samples were
stored at 30 C + 2 C, the value of the zeta-potential obtained after
30 days was not much lower than that obtained after the samples
were stored for 10 days without a medium. Due to the high content
in salts of the media used and the negative values of their zeta-
potentials, these seem to cause problems for the stability of the li-
pid samples. It would appear that the most suitable medium for
preparing fresh samples and being able to work with them over
a short period of time (up to 24 h) is the HBS medium.m (a); DMEM-Ab medium (b) and HBS medium (c) from the initial t = 0.
(a); DMEM-Ab medium (b) and HBS medium (c) 24 h after formulation.
(a); DMEM-Ab medium (b) and HBS medium (c) 10 days after formulation.
olid lipid nanoparticles (SLNs). Eur. J. Pharm. Sci. (2013), http://dx.doi.org/
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Fig. 13. SEM images for the SLN samples stored at 30 ± 2 C in DMEM medium (a); DMEM-Ab medium (b) and HBS medium (c) 30 days after formulation.
1     2      3     4      5     6     7     8    9     10 SLN:DNA ratio      
1:   DNA 
2:   15:1 
3:   10:1 
4:   7:1 
5:   6:1 
6:   5:1 
7:   4:1 
8:   3:1 
9:   2.5:1 
10: 1:1 
Fig. 14. Agarose gel electrophoresis of SLN: DNA at different ratios (v/v). DNA:
pEFBOSGFP-FF5 (5600 pb approx.) (25 ll of 2 lg/ll in each reaction). Ratios: SLN/
DNA vol:vol (ll/ll).
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2 March 2013The electron microscopy images for the samples stored at
30 C ± 2 C in the DMEM and DMEM-Ab media, right from the ini-
tial t = 0 showed a certain degree of agglomeration of the nanopar-
ticles (Fig. 10a and b). In contrast, in the HBS medium, a greater
number of particles that did not agglomerate were observed
(Fig. 10c). In general, 24 h after formulation, the SLNs showedmore
agglomeration in all media, although to a lesser extent in the HBS
(Fig. 11a–c). After 10 days in all media a greater number of aggre-
gates were detected (Figs. 12 and 13), and in some samples, as was
the case of the DMEM-Ab medium (Figs. 12b and 13b), no particles
were observed that had not formed agglomerations.
3.6. Agarose gel electrophoresis
The loading efficiency of the cationic SLNs with respect to the
plasmid DNA can be detected from Fig. 14 which shows the results
obtained in the agarose gel electrophoresis. Certain concentrations
of SLNs can be observed to form bonds with the plasmids; while as
the ratio decreases the free DNA signal is observed. Below a pro-
portion of 4:1 (SLN:DNA), free DNA is left that has not bonded to
the cationic lipid nanoparticles, while the most favorable propor-
tions for bonding to occur are those between 15:1 and 5:1.429
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4434. Conclusions
Cationic SLNs were obtained by the method described, with a
size of 340 nm and with a surface charge of approximately
+44 mV. Morphological analyses showed that they were smooth
spherical nanoparticles and that there were no interactions or
polymorphs formed between the products used in the formulation
of the nanoparticles.
After the process of lyophilization, resuspension of the lyophi-
lized sample was best achieved when the cryoprotectant trehalosePlease cite this article in press as: Carrillo, C., et al. DNA delivery via cationic s
10.1016/j.ejps.2013.02.011was used at a concentration of 10%; nanoparticles with the same
size and surface charge characteristics as those of the initial nano-
particles were obtained. Using a concentration of 5% of trehalose
and after the application of ultrasound in the resuspension of the
lyophilized sample these characteristics were also achieved.
Storing the samples at a temperature of 30 ± 2 C in hermeti-
cally sealed vials, the fresh cationic SLNs with no addition of a
medium were considered to be stable for approximately 10 days.
Of the media used, samples showed greatest stability in the HBS
medium for the first 24 h after formulation. None of the media
could be used to guarantee the stability of the fresh cationic SLNs
after 24 h stored at this temperature, as agglomerations of the
product formed and physical and chemical changes occurred.
The method developed is suitable for obtaining cationic SLNs
that can form a complex with plasmid DNA (lipoplexes).The most
efficient proportions for the formation of such lipoplexes is be-
tween 15:1 and 5:1 (v/v) of SLN:plasmid DNA.
This study shows that the method developed at this point pro-
duces cationic SLNs that are effectively loaded with plasmid DNA.
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